SG11201400988SA - Compounds and methods for enhancing innate immune responses - Google Patents
Compounds and methods for enhancing innate immune responsesInfo
- Publication number
- SG11201400988SA SG11201400988SA SG11201400988SA SG11201400988SA SG11201400988SA SG 11201400988S A SG11201400988S A SG 11201400988SA SG 11201400988S A SG11201400988S A SG 11201400988SA SG 11201400988S A SG11201400988S A SG 11201400988SA SG 11201400988S A SG11201400988S A SG 11201400988SA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- methods
- immune responses
- innate immune
- enhancing innate
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000015788 innate immune response Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549784P | 2011-10-21 | 2011-10-21 | |
| US201261692431P | 2012-08-23 | 2012-08-23 | |
| PCT/US2012/060971 WO2013059559A2 (en) | 2011-10-21 | 2012-10-19 | Compounds and methods for enhancing innate immune responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201400988SA true SG11201400988SA (en) | 2014-07-30 |
Family
ID=48141628
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201505664WA SG10201505664WA (en) | 2011-10-21 | 2012-10-19 | Compounds and methods for enhancing innate immune responses |
| SG11201400988SA SG11201400988SA (en) | 2011-10-21 | 2012-10-19 | Compounds and methods for enhancing innate immune responses |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201505664WA SG10201505664WA (en) | 2011-10-21 | 2012-10-19 | Compounds and methods for enhancing innate immune responses |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20140249143A1 (enExample) |
| EP (1) | EP2768506A4 (enExample) |
| JP (1) | JP2014532626A (enExample) |
| KR (1) | KR20140094559A (enExample) |
| CN (1) | CN103957910A (enExample) |
| AR (1) | AR088793A1 (enExample) |
| AU (1) | AU2012325971B2 (enExample) |
| BR (1) | BR112014008727A2 (enExample) |
| CA (1) | CA2851801A1 (enExample) |
| CL (1) | CL2014001016A1 (enExample) |
| CO (1) | CO6910198A2 (enExample) |
| CR (1) | CR20140175A (enExample) |
| DO (1) | DOP2014000081A (enExample) |
| EA (1) | EA201490610A1 (enExample) |
| IL (1) | IL231894A0 (enExample) |
| MX (1) | MX2014004814A (enExample) |
| PE (1) | PE20141359A1 (enExample) |
| PH (1) | PH12014500865A1 (enExample) |
| SG (2) | SG10201505664WA (enExample) |
| TW (2) | TW201333003A (enExample) |
| UY (1) | UY34406A (enExample) |
| WO (1) | WO2013059559A2 (enExample) |
| ZA (1) | ZA201402392B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103333168B (zh) * | 2013-07-23 | 2015-08-05 | 清华大学 | 一种酰胺类化合物及其制备方法与应用 |
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| WO2016053893A1 (en) * | 2014-09-29 | 2016-04-07 | The Trustees Of The University Of Pennsylvania | Antivirals against molluscum contagiosum virus |
| CN104529893B (zh) * | 2014-12-30 | 2016-08-24 | 中国科学技术大学 | 一类可以作为高尔基体细胞器探针的喹啉染料 |
| CN105175277B (zh) * | 2015-05-18 | 2018-04-03 | 中山大学肿瘤防治中心 | 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用 |
| WO2018043747A1 (ja) * | 2016-09-05 | 2018-03-08 | 国立大学法人京都大学 | 抗ｂ型肝炎ウイルス剤 |
| CN110709400A (zh) | 2017-03-28 | 2020-01-17 | 皮梅拉股份有限公司 | Pol1抑制剂的新型晶体形式 |
| UA127747C2 (uk) | 2018-10-23 | 2023-12-20 | Басф Се | Трициклічні пестицидні сполуки |
| CN114732823B (zh) * | 2019-03-13 | 2023-05-23 | 中国人民解放军军事科学院军事医学研究院 | 氨基葡萄糖及其衍生物作为抗病毒药物的应用 |
| EP4136086A1 (en) | 2020-04-14 | 2023-02-22 | Basf Se | Tricyclic pesticidal compounds |
| JP2023539896A (ja) * | 2020-09-03 | 2023-09-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｓａｒｓ－ｃｏｖ－２感染を治療するためのｉｆｎａｒ２アゴニストとしてのイミダゾナフチリジンおよびイミダゾピリドピリミジン |
| WO2022175425A1 (en) | 2021-02-22 | 2022-08-25 | Glaxosmithkline Intellectual Property Development Limited | Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| WO2023056421A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| MX2024004444A (es) | 2021-10-14 | 2024-05-08 | Incyte Corp | Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras). |
| WO2023244672A1 (en) | 2022-06-14 | 2023-12-21 | Assembly Biosciences, Inc. | 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections |
| AU2024252826A1 (en) * | 2023-04-14 | 2025-10-16 | HUMANWELL PHARMACEUTICAL US, Inc. | Monoacylglycerol lipase (magl) inhibitors for the treatment of pain and related medical disorders |
| WO2025089372A1 (ja) * | 2023-10-26 | 2025-05-01 | 国立研究開発法人理化学研究所 | イソインドリン誘導体 |
| WO2025128898A1 (en) | 2023-12-13 | 2025-06-19 | Assembly Biosciences, Inc. | Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL59104A (en) * | 1979-02-09 | 1984-02-29 | Roussel Uclaf | Heterotricyclic derivatives,process for their preparation and pharmaceutical compositions incorporating them |
| US4492697A (en) * | 1983-08-16 | 1985-01-08 | Ayerst, Mckenna & Harrison, Inc. | 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives |
| US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| PL374544A1 (en) * | 2002-04-03 | 2005-10-31 | F.Hoffmann-La Roche Ag | Imidazo fused compounds |
| US8592368B2 (en) * | 2003-12-19 | 2013-11-26 | University Of South Florida | JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection |
| DE102005019181A1 (de) * | 2005-04-25 | 2006-10-26 | Novartis Ag | Peptid-Deformylase (PDF) Inhibitoren 1 |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| EP2416488B1 (en) * | 2009-03-31 | 2019-03-06 | Daikin Industries, Ltd. | Electrode film for polymer actuator element, and polymer actuator element comprising same |
| GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB201002409D0 (en) * | 2010-02-12 | 2010-03-31 | Univ Nottingham | Methods |
-
2012
- 2012-10-19 JP JP2014537274A patent/JP2014532626A/ja active Pending
- 2012-10-19 WO PCT/US2012/060971 patent/WO2013059559A2/en not_active Ceased
- 2012-10-19 EA EA201490610A patent/EA201490610A1/ru unknown
- 2012-10-19 MX MX2014004814A patent/MX2014004814A/es unknown
- 2012-10-19 PE PE2014000559A patent/PE20141359A1/es not_active Application Discontinuation
- 2012-10-19 KR KR1020147013668A patent/KR20140094559A/ko not_active Withdrawn
- 2012-10-19 BR BR112014008727A patent/BR112014008727A2/pt not_active IP Right Cessation
- 2012-10-19 CN CN201280051347.8A patent/CN103957910A/zh active Pending
- 2012-10-19 US US14/353,067 patent/US20140249143A1/en not_active Abandoned
- 2012-10-19 SG SG10201505664WA patent/SG10201505664WA/en unknown
- 2012-10-19 PH PH1/2014/500865A patent/PH12014500865A1/en unknown
- 2012-10-19 CA CA2851801A patent/CA2851801A1/en not_active Abandoned
- 2012-10-19 AU AU2012325971A patent/AU2012325971B2/en not_active Ceased
- 2012-10-19 SG SG11201400988SA patent/SG11201400988SA/en unknown
- 2012-10-19 EP EP12840986.9A patent/EP2768506A4/en not_active Withdrawn
- 2012-10-22 UY UY0001034406A patent/UY34406A/es not_active Application Discontinuation
- 2012-10-22 TW TW101138997A patent/TW201333003A/zh unknown
- 2012-10-22 AR ARP120103945A patent/AR088793A1/es unknown
- 2012-10-22 TW TW104126180A patent/TW201542567A/zh unknown
-
2014
- 2014-03-18 CO CO14058151A patent/CO6910198A2/es unknown
- 2014-03-31 ZA ZA2014/02392A patent/ZA201402392B/en unknown
- 2014-04-03 IL IL231894A patent/IL231894A0/en unknown
- 2014-04-21 DO DO2014000081A patent/DOP2014000081A/es unknown
- 2014-04-21 CL CL2014001016A patent/CL2014001016A1/es unknown
- 2014-04-21 CR CR20140175A patent/CR20140175A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014008727A2 (pt) | 2017-04-25 |
| WO2013059559A3 (en) | 2013-11-14 |
| DOP2014000081A (es) | 2014-07-15 |
| EP2768506A4 (en) | 2015-08-19 |
| WO2013059559A2 (en) | 2013-04-25 |
| EA201490610A1 (ru) | 2014-09-30 |
| SG10201505664WA (en) | 2015-09-29 |
| MX2014004814A (es) | 2014-05-27 |
| KR20140094559A (ko) | 2014-07-30 |
| EP2768506A2 (en) | 2014-08-27 |
| PH12014500865A1 (en) | 2014-05-26 |
| AU2012325971A1 (en) | 2014-04-17 |
| CO6910198A2 (es) | 2014-03-31 |
| TW201542567A (zh) | 2015-11-16 |
| AU2012325971B2 (en) | 2016-03-31 |
| AR088793A1 (es) | 2014-07-10 |
| CR20140175A (es) | 2014-06-03 |
| PE20141359A1 (es) | 2014-10-13 |
| CL2014001016A1 (es) | 2015-01-16 |
| ZA201402392B (en) | 2017-09-27 |
| IL231894A0 (en) | 2014-05-28 |
| CN103957910A (zh) | 2014-07-30 |
| UY34406A (es) | 2013-05-31 |
| TW201333003A (zh) | 2013-08-16 |
| US20140249143A1 (en) | 2014-09-04 |
| JP2014532626A (ja) | 2014-12-08 |
| CA2851801A1 (en) | 2013-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL231894A0 (en) | Compounds and methods for enhancing innate immune responses | |
| ZA201307919B (en) | Composition and method for enhancing an immune response | |
| EP2736330A4 (en) | COMPOUNDS AND METHODS | |
| EP2747560A4 (en) | CONNECTIONS AND METHODS | |
| PL2696754T3 (pl) | Urządzenie i sposób pomiaru stresu | |
| EP2615533A4 (en) | INTERACTION PROCEDURE AND INTERACTION DEVICE | |
| EP2788507A4 (en) | METHOD FOR MEASURING IMMUNE ACTIVATION | |
| EP2736332A4 (en) | CONNECTIONS AND METHODS | |
| IL232213A0 (en) | Antibody Formulations and Methods | |
| EP2736329A4 (en) | COMPOUNDS AND METHODS | |
| GB201110783D0 (en) | Methods and uses | |
| GB201122089D0 (en) | Telecomunication apparatus and methods | |
| EP2755363A4 (en) | METHOD AND DEVICE FOR FAST DATA DISTRIBUTION | |
| GB201116774D0 (en) | Uses and methods | |
| EP2753062A4 (en) | IMAGING DEVICE AND IMAGING METHOD | |
| GB201101862D0 (en) | Method and device | |
| SG11201408326TA (en) | Preparation method for perfluoro-2-methyl-3-pentanone and intermediate | |
| EP2741748A4 (en) | BETA-LACTAM COMPOUNDS FOR IMPROVING T-CELL-MEDIATED IMMUNE REACTIONS | |
| GB201105569D0 (en) | Apparatus and methods | |
| EP2717985A4 (en) | DEVICE AND METHOD FOR DISTILLATION | |
| GB201113806D0 (en) | Food processing | |
| GB201108490D0 (en) | Methods and uses | |
| ZA201400185B (en) | Food suspension device | |
| HK1195257A (en) | Compounds and methods for enhancing innate immune responses | |
| EP2756880A4 (en) | DEVICE FOR TREATING POWDERS AND METHOD THEREOF |